
Jinal Harenbhai Patel
About Jinal Harenbhai Patel
Data last updated:
Jinal Harenbhai Patel has 8 years in corporate governance. Holds Director and Designated Partner roles. Currently with 2 companies, including Lubgraf Synoils Pvt Ltd and Ixa Pharma Llp. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Lubgraf Synoils Pvt Ltd at ₹36.80 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 15 Jan 2018 | 1995 | ₹36.80 Cr (FY 2025) | Active | |
| Designated Partner | 21 Dec 2023 | 2023 | – | Active |
Previous companies
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Jinal Harenbhai Patel
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jinal Harenbhai Patel
Jinal Harenbhai Patel has 8 years in corporate governance. Holds Director and Designated Partner roles. Currently with 2 companies, including Lubgraf Synoils Pvt Ltd and Ixa Pharma Llp. Engaged in General Business. Contributes to corporate operations. The largest current company by reported revenue is Lubgraf Synoils Pvt Ltd at ₹36.80 Cr (FY 2025).
Jinal Harenbhai Patel is associated with 2 companies as Director and Designated Partner, including Lubgraf Synoils Pvt Ltd (₹36.80 Cr), Ixa Pharma Llp.
Jinal Harenbhai Patel has expertise in General Business.
Jinal Harenbhai Patel has 8 years in corporate governance.
By reported revenue, the largest current company of Jinal Harenbhai Patel is Lubgraf Synoils Pvt Ltd, with revenue of ₹36.80 Cr (FY 2025).
Jinal Harenbhai Patel currently holds positions at 2 companies: Lubgraf Synoils Pvt Ltd (₹36.80 Cr), Ixa Pharma Llp.